当前，未名拾光探索出符合美妆日化、医疗器械、食品行业需求的商业模式，一方面自研创新原料管 线；另一方面以CRDMO模式（CRO+CDMO），与下游品牌商合作开发新型生物原料，并为之提供新 原料的代工生产服务，以兼备效率和确定性。 AI引擎与双底盘细胞工厂 36氪获悉，「未名拾光」近日获得数千万元人民币B+轮融资，由华泰金斯瑞、海邦投资共同投资。本 轮融资将主要用于深化AI技术平台建设、拓展生物材料多元应用场景，及加速业务全球化布局。 继今年5月获欧莱雅、纳爱斯集团投资的近亿元后，未名拾光再获产业基金加持。 创始人赵亚冉告诉36氪，未名拾光创立之初，在搭建技术平台时就非常关注生物材料的创新，构建了生 物活性分子设计、筛选、功效评估到规模化生产的闭环，且通过AI全面赋能该合成生物技术平台。 当前未名拾光开发的具体生物原料品类，主要包括两类：植物愈伤组织，如获批备案的新化妆品原 料"昙花愈伤组织提取物"、"华白及愈伤组织提取物"、 "牡丹愈伤组织提取物；生物活性蛋白，包括重 组胶原蛋白、多肽等。 该模式在植物代谢产物等品类上得到了验证，为之拓展了多个国内外知名品牌客户，客户数量已经超过 胶原蛋白品类。 一方面，未名 ...

Core Viewpoint - The company "未名拾光" has recently secured a B+ round financing of several tens of millions of RMB, following a previous investment of nearly 100 million RMB from L'Oréal and Naive Group, aimed at enhancing its AI technology platform and expanding its global business footprint [3][4]. Group 1: Financing and Investment - "未名拾光" has received significant investments from both L'Oréal and Naive Group, totaling nearly 100 million RMB earlier this year, and has now attracted additional funding from industrial funds [4]. - The latest financing round will primarily focus on deepening AI technology platform development and expanding the application scenarios of biological materials [3]. Group 2: Technology and Product Development - The company has established a closed-loop system for the innovation of biological materials, integrating design, screening, efficacy evaluation, and large-scale production, empowered by AI [4]. - "未名拾光" is developing two main categories of biological raw materials: plant callus tissues and bioactive proteins, including recombinant collagen and peptides [4]. - The company has created a dual-cell factory system utilizing both microbial and plant cell factories to produce various products, including rare plant active molecules [6]. Group 3: AI Integration - The team recognized the value of AI early in the development of their synthetic biology technology platform, utilizing tools like AlphaFold and RFDiffusion to enhance research efficiency [7]. - AI has significantly improved research efficiency, reportedly increasing it by at least five times, with plans to allocate 50% of R&D spending towards AI development [8]. Group 4: Business Model and Market Strategy - "未名拾光" employs a CRDMO model (CRO + CDMO) to collaborate with downstream brand partners for the development of new biological raw materials and provide contract manufacturing services [4][10]. - The company has successfully validated its model in the plant metabolite category, expanding its client base to include numerous well-known domestic and international brands [11]. Group 5: Future Directions - The company plans to expand its business in bioactive raw materials from the beauty sector to food and daily chemical applications, while also seeking international market opportunities [13].